Bivalent Ligands for Protein Degradation in Drug Discovery

Area of Science:

• Drug Discovery
• Molecular Biology
• Biochemistry

Background:

• Targeting the
• undruggable
• proteome is a major challenge in drug discovery.
• Conventional inhibitors are ineffective against certain disease-related proteins.
• Innovations in targeted protein degradation offer new therapeutic avenues.

Purpose of the Study:

• To provide a comprehensive overview of recent advancements in small molecule-mediated protein degradation.
• To discuss the potential benefits of protein degradation over inhibition.
• To highlight challenges in the field of targeted protein degradation.

Main Methods:

• Review of recent developments in proteolysis targeting chimeras (PROTACs).
• Discussion of bivalent ligands that recruit E3 ligases (e.g., Cereblon, Von Hippel-Lindau) to target proteins.
• Analysis of PROTAC applications in studying transcription factors, kinases, and nuclear receptors.

Main Results:

• PROTACs are bivalent ligands that induce targeted protein degradation.
• Selective PROTAC molecules demonstrate potent effects in cellular and in vivo models.
• Protein degradation offers greater specificity than traditional inhibitor compounds for studying biological pathways.

Conclusions:

• Targeted protein degradation represents a promising therapeutic strategy for challenging targets.
• PROTAC technology facilitates the study of complex biological systems with enhanced precision.
• Overcoming current challenges is crucial for the broader clinical application of protein degradation therapies.